Abstract:BACKGROUND:Evidence suggests that many types of cancers are composed of different cell types, including cancer stem cells (CSCs). We have previously shown that the chemotherapeutic agent oxaliplatin induced epithelial-mesenchymal transition, which is thought to be an important mechanism for generating CSCs. In the present study, we investigate whether oxaliplatin-treated cancer tissues possess characteristics of CSCs, and explore oxaliplatin resistance in these tissues.METHODS:Hepatocellular carcinoma cells (MHCC97H cells) were subcutaneously injected into mice to form tumors, and the mice were intravenously treated with either oxaliplatin or glucose. Five weeks later, the tumors were orthotopically xenografted into livers of other mice, and these mice were treated with either oxaliplatin or glucose. Metastatic potential, sensitivity to oxaliplatin, and expression of CSC-related markers in the xenografted tumor tissues were evaluated. DNA microarrays were used to measure changes in gene expression as a result of oxaliplatin treatment. Additionally, an oxaliplatin-resistant cell line (MHCC97H-OXA) was established to assess insulin-like growth factor 1 secretion, cell invasion, cell colony formation, oxaliplatin sensitivity, and expression of CSC-related markers. The effects of an insulin-like growth factor 1 receptor inhibitor were also assessed.RESULTS:Oxaliplatin treatment inhibited subcutaneous tumor growth. Tumors from oxaliplatin-treated mice that were subsequently xenografted into livers of other mice exhibited that decreasing sensitivity to oxaliplatin and increasing pulmonary metastatic potential. Among the expression of CSC-related proteins, the gene for insulin-like growth factor 1, was up-regulated expecially in these tumor tissues. Additionally, MHCC97H-OXA cells demonstrated that increasing cell invasion, colony formation, and expression of insulin-like growth factor 1 and CSC-related markers, whereas treatment with an inhibitor of the insulin-like growth factor 1 receptor suppressed these effects.CONCLUSION:Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma cells is associated with increased autocrine of IGF1.

HSP90a Promotes the Resistance to Oxaliplatin in HCC Through Regulating IDH1-induced Cell Competition.

ID1 Promotes Hepatocellular Carcinoma Proliferation and Confers Chemoresistance to Oxaliplatin by Activating Pentose Phosphate Pathway

The HSP90AB1-mediated upregulation of IDO1 can promote the progression of colorectal cancer

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

Epithelial–mesenchymal Transition Plays a Critical Role in Drug Resistance of Hepatocellular Carcinoma Cells to Oxaliplatin

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment

Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma is Associated with Increased Autocrine of IGF1.

HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy

Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway

Heterogeneous Responses and Isoform Compensation Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer

Heat Shock Protein 90 Promotes RNA Helicase DDX5 Accumulation and Exacerbates Liver Cancer by Inhibiting Autophagy

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

Targeting HSP90 Inhibits Proliferation and Induces Apoptosis Through AKT1/ERK Pathway in Lung Cancer

HSF1/AMPKα2 Mediated Alteration of Metabolic Phenotypes Confers Increased Oxaliplatin Resistance in HCC Cells.

Self-enforcing HMGB1/NF-κB/HIF-1α Feedback Loop Promotes Cisplatin Resistance in Hepatocellular Carcinoma Cells

Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy

Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target

Single-cell RNA Sequencing Reveals That Targeting HSP90 Suppresses PDAC Progression by Restraining Mitochondrial Bioenergetics

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials